LIVE
AMGN
Amgen Inc. · Healthcare
$337.60
+2.07% this month
VERSUS
⟷
COMPARE
ABBV
AbbVie Inc. · Healthcare
$216.49
+1.28% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
AMGN
1
ABBV
4
Comparison scoreboard
ABBV LEADS 4/5AI Score
AMGN 47.3
ABBV ✓52.0
1Y Return
AMGN +16.39%
ABBV ✓+16.72%
Fwd P/E
AMGN 14.38
ABBV ✓13.32
Target Up.
AMGN +4.49%
ABBV ✓+17.12%
Op. Margin
AMGN ✓33.80%
ABBV 32.16%
Metrics last refreshed: 6/22/2026
Quick take
AMGN vs ABBV Stock Comparison: AI Score, Valuation, Performance and Upside
Amgen and AbbVie are both large-cap biopharmaceutical dividend companies with significant pipeline transitions underway. Amgen is pivoting toward obesity (MariTide), oncology (Imdelltra), and biosimilars. AbbVie is replacing Humira with Skyrizi and Rinvoq in immunology while Botox provides aesthetic stability. Both pay substantial dividends and have high-quality drug pipelines, but their near-term catalysts are very different — MariTide obesity data for Amgen vs Skyrizi/Rinvoq execution for AbbVie.
AMGN vs ABBV is the biotech pioneer with a potential obesity drug wildcard (MariTide) and expanding biosimilar business (Amgen) versus the immunology specialist replacing Humira with faster-growing Skyrizi/Rinvoq while Botox provides aesthetics stability (AbbVie) — two exceptional healthcare income compounders with different growth catalysts.
Live analysis · updated 6/22/2026
ABBV holds the edge across 4 of 5 key metrics in this comparison. ABBV leads on both 1-year return (+16.72%) and forward P/E (13.32x vs 14.38x for AMGN), a relatively favorable combination of momentum and valuation. On fundamentals, ABBV is growing revenue faster (12.40%), while AMGN maintains the higher operating margin (33.80%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for ABBV (+17.12%) than for AMGN (+4.49%).
Normalized 1Y performance
AMGN
ABBV
Recent returns
AMGN
ABBV
Analyst price targets & sentiment
AMGN · 28 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.4/5.0)
Price target range
analyst low$185.00
analyst high$400.00
analyst mean$352.77
current price$337.60
+4.5% upside to analyst mean
ABBV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$170.00
analyst mean$253.55
current price$216.49
+17.1% upside to analyst mean
Who should consider this stock?
AMGN may suit investors who:
- →prefer Amgen's diversification across cardiovascular (Repatha), rare disease (Tepezza, Krystexxa), oncology bispecifics (Imdelltra), and potential obesity (MariTide) pipeline
- →value MariTide Phase 3 as a massive optional call option — success would add a blockbuster obesity drug to Amgen's revenue base competing with Lilly and Novo Nordisk
- →want biosimilar revenue diversification as Amgen's growing biosimilar portfolio capitalizes on brand biologic patent expirations
- →are comfortable with Enbrel biosimilar revenue erosion, MariTide Phase 3 uncertainty, and Horizon acquisition integration execution risk
ABBV may suit investors who:
- →prefer the immunology replacement story — Skyrizi and Rinvoq's rapid growth is on track to more than offset Humira biosimilar decline by 2027
- →value AbbVie's Botox aesthetic franchise as a uniquely brand-protected premium product with durable pricing in medical and aesthetic neurotoxin applications
- →want the highest near-term dividend yield among large-cap pharma with strong dividend growth commitment
- →are comfortable with Humira revenue decline through 2026, immunology competition in Skyrizi/Rinvoq indications, and aesthetics market cyclicality
Performance & AI score
| Metric | AMGN | ABBV |
|---|---|---|
| AI score | 47.3 | 52.0 |
| AI rank | #625 | #346 |
| Latest close | $337.60 | $216.49 |
| 1M return | +2.07% | +1.28% |
| 6M return | +3.56% | -3.49% |
| 1Y return | +16.39% | +16.72% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | ABBV |
|---|---|---|
| 1Y ago | $11.66K (+16.6%) started 2025-06-18 | $11.67K (+16.7%) started 2025-06-18 |
| 5Y ago | $18.29K (+82.9%) started 2021-06-21 | $26.07K (+160.7%) started 2021-06-21 |
| 10Y ago | $39.81K (+298.1%) started 2016-06-20 | $83.39K (+733.9%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | AMGN | ABBV |
|---|---|---|
| Market cap | $182.21B | $382.49B |
| Trailing P/E | 23.48 | 106.12 |
| Forward P/E | 14.38 | 13.32 |
| Price/Sales | 4.57 | 5.85 |
| EV/Revenue | 6.11 | 7.10 |
| Analyst target | $352.77 | $253.55 |
| Target upside | +4.49% | +17.12% |
Growth, profitability & risk
| Metric | AMGN | ABBV |
|---|---|---|
| Revenue growth | 5.80% | 12.40% |
| Earnings growth | 4.40% | -46.20% |
| EPS growth | +4.40% | -46.20% |
| FCF margin | +19.98% | +33.13% |
| Operating margin | 33.80% | 32.16% |
| Profit margin | 20.96% | 5.79% |
| ROIC proxy | 101.32% | 6225.00% |
| Return on equity | 101.32% | 6225.00% |
| Dividend yield | 2.99% | 3.20% |
| Beta | 0.42 | 0.31 |
| Debt/equity | 623.75 | 4789.60 |
| Current ratio | 1.26 | 0.80 |
| Quick ratio | 0.85 | 0.52 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
AMGN max drawdown16.57%
ABBV max drawdown19.23%
AMGN max wkly drop8.70%
ABBV max wkly drop8.49%
5Y risk snapshot
AMGN max drawdown24.86%
ABBV max drawdown21.92%
AMGN max wkly drop12.81%
ABBV max wkly drop17.30%
10Y risk snapshot
AMGN max drawdown24.86%
ABBV max drawdown45.09%
AMGN max wkly drop15.79%
ABBV max wkly drop19.39%
Performance metrics by period
| Period | Metric | AMGN | ABBV |
|---|---|---|---|
| 1Y | Growth | +16.56% | +16.71% |
| CAGR | +16.59% | +16.74% | |
| Sharpe ratio | 0.53 | 0.57 | |
| Max drawdown | 16.57% | 19.23% | |
| Max daily drop | 5.84% | 5.20% | |
| Max wkly drop | 8.70% | 8.49% | |
| 5Y | Growth | +59.69% | +120.43% |
| CAGR | +9.83% | +17.16% | |
| Sharpe ratio | 0.32 | 0.61 | |
| Max drawdown | 24.86% | 21.92% | |
| Max daily drop | 7.14% | 12.57% | |
| Max wkly drop | 12.81% | 17.30% | |
| 10Y | Growth | +193.14% | +426.67% |
| CAGR | +11.36% | +18.09% | |
| Sharpe ratio | 0.38 | 0.60 | |
| Max drawdown | 24.86% | 45.09% | |
| Max daily drop | 9.58% | 16.25% | |
| Max wkly drop | 15.79% | 19.39% |
Business comparison
| Category | AMGN | ABBV |
|---|---|---|
| Company | Amgen Inc. | AbbVie Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Amgen is the world's largest independent biotechnology company, pioneering biological medicines (proteins produced in living cells). Key products include Repatha (cholesterol/cardiovascular), Otezla (dermatology), Enbrel (rheumatology, losing market share to biosimilars), Prolia/Xgeva (bone health), and expanding into obesity (MariTide — once-monthly injection GLP-1/GIP antagonist). Amgen's Horizon acquisition added Tepezza (thyroid eye disease) and Krystexxa (gout). Amgen is investing in next-generation bispecific antibodies (Imdelltra for small cell lung cancer) and biosimilar medicines competing with original biologics from competitors. | AbbVie is a biopharmaceutical company replacing $20B+ Humira revenue through Skyrizi (risankizumab for psoriasis, IBD) and Rinvoq (upadacitinib for rheumatoid arthritis, atopic dermatitis). AbbVie's Allergan acquisition added Botox, aesthetic fillers, and eye care products. Both Skyrizi and Rinvoq are growing 40–50% annually as Humira declines from biosimilar competition. AbbVie is also developing oncology programs (NaviNe, Epcoritamab) to further diversify beyond immunology. |
| Investor focus | Investors track MariTide obesity drug Phase 3 data (the most important upcoming catalyst), Repatha cardiovascular revenue growth, biosimilar pipeline approvals and sales, and post-Horizon acquisition integration. | Investors track Skyrizi and Rinvoq combined revenue growth vs Humira decline, Botox aesthetics revenue, and new indication approvals for Skyrizi and Rinvoq expanding into new diseases. |
AMGN strengths
- →MariTide GLP-1/GIP obesity program represents potential blockbuster — monthly injection vs weekly Ozempic/Wegovy could offer dosing advantage if Phase 3 proves out
- →Biotech pioneer with exceptional R&D capabilities across oncology, cardiometabolic, and inflammatory disease — decades of biological manufacturing expertise
- →Biosimilar business (Amgevita, Riabni, Mvasi) creates additional revenue from competing against brand biologics coming off patent
ABBV strengths
- →Skyrizi and Rinvoq are both best-in-class immunology drugs with multiple approved indications — AbbVie projects their combined peak revenue exceeding Humira's $20B+ at peak
- →Botox aesthetic monopoly position with limited near-term biosimilar risk — the Botox brand has decades of consumer recognition
- →Immunology expertise built over Humira decades provides deep clinical/regulatory knowledge for next-generation drug development
Risks to watch — AMGN
- →MariTide Phase 3 trials are critical — the obesity market is the largest pharmaceutical opportunity in decades but MariTide must compete with Eli Lilly's Zepbound and Novo Nordisk's Wegovy
- →Enbrel biosimilar competition continues eroding one of Amgen's historically important revenue streams
- →Horizon integration ($27.8B acquisition) requires successful commercialization of Tepezza and Krystexxa in rare disease indications
Risks to watch — ABBV
- →Humira revenue decline will be substantial through 2026 before Skyrizi/Rinvoq growth fully offsets it
- →Immunology competition from AstraZeneca, Pfizer, and Eli Lilly in psoriasis, RA, and IBD indications
- →Aesthetics market cyclicality during economic downturns can pressure Botox and filler demand
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →